- Home
- NECB vs NNNN Comparison
NECB vs NNNN Comparison
Compare NECB & NNNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NECB
- NNNN
- Stock Information
- Founded
- NECB 1934
- NNNN 2021
- Country
- NECB United States
- NNNN Germany
- Employees
- NECB N/A
- NNNN N/A
- Industry
- NECB Savings Institutions
- NNNN Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- NECB Finance
- NNNN Health Care
- Exchange
- NECB Nasdaq
- NNNN Nasdaq
- Market Cap
- NECB 263.6M
- NNNN 267.7M
- IPO Year
- NECB N/A
- NNNN 2025
- Fundamental
- Price
- NECB $23.22
- NNNN $6.43
- Analyst Decision
- NECB
- NNNN
- Analyst Count
- NECB 0
- NNNN 0
- Target Price
- NECB N/A
- NNNN N/A
- AVG Volume (30 Days)
- NECB 36.9K
- NNNN 28.8K
- Earning Date
- NECB 04-21-2025
- NNNN 01-01-0001
- Dividend Yield
- NECB 3.21%
- NNNN N/A
- EPS Growth
- NECB 0.72
- NNNN N/A
- EPS
- NECB 3.44
- NNNN 0.06
- Revenue
- NECB $104,392,000.00
- NNNN $8,185,146.00
- Revenue This Year
- NECB $2.80
- NNNN N/A
- Revenue Next Year
- NECB $8.34
- NNNN N/A
- P/E Ratio
- NECB $6.88
- NNNN $118.17
- Revenue Growth
- NECB 2.77
- NNNN 21.95
- 52 Week Low
- NECB $16.51
- NNNN $5.18
- 52 Week High
- NECB $31.72
- NNNN $7.82
- Technical
- Relative Strength Index (RSI)
- NECB 55.63
- NNNN N/A
- Support Level
- NECB $22.85
- NNNN N/A
- Resistance Level
- NECB $23.90
- NNNN N/A
- Average True Range (ATR)
- NECB 0.76
- NNNN 0.00
- MACD
- NECB 0.14
- NNNN 0.00
- Stochastic Oscillator
- NECB 77.33
- NNNN 0.00
About NECB NorthEast Community Bancorp Inc.
NorthEast Community Bancorp Inc operates as a community-oriented financial institution. It is principally engaged in the business of attracting deposits and investing those funds into mortgage and commercial loans. It conducts activities throughout the Northeastern United States including New York, Massachusetts, New Jersey, and Connecticut. The company offers a comprehensive line of banking products and services, including mobile banking as well as commercial real estate loans, commercial construction financing, lines of credit, and term loans. It also offers investment advisory and financial planning services.
About NNNN Anbio Biotechnology Class A Ordinary Shares
Anbio Biotechnology is a medical device company focused on in vitro diagnostics. It offers laboratory, wellness, at-home, and point-of-care (POCT) in vitro diagnostic (IVD) solutions to detect a wide range of biomarkers associated with critical medical domains encompassing infectious diseases, cancer, cardiovascular diseases, inflammation, drug abuse, endocrine disorders, renal disease, pharmacogenomics, and diabetes. Its product portfolio comprises AF-1200 Fluorescence Immunoassay Analyzer, SHA-100 Dry Chemistry Analyzer, Ferritin Rapid Test Kit, Dengue NS1 Rapid Test, Multi-HBV Rapid Test, COVID-19 Test Kit (Real-time PCR), and others. Geographically, the company generates maximum revenue from the European Union, followed by South America, Asia Pacific, North America, and other regions.